100 High Myopia Patient-reported Outcomes (PRO) and Performance Outcomes (PERFO)

Pathological Myopia and Quality of Life: An Exploratory Study of Patient Outcomes and Perceptions

Prospective, longitudinal, interventional, exploratory, non-randomized, single-center study including patients with pathological myopia .

This project will be conducted in two phases, with a qualitative study and an exploratory phase.

There is a clinical need to better understand the progression of myopic complications with diffuse choroidal atrophy (DCA Cat. 2) and choroidal patch atrophy (CPA Cat. 3) and their impact on everyday life.

The first phase is a qualitative study whose objectives are

1. to study the parameters (ceiling and floor effects) and assess the reliability of performance tasks in relation to perceived difficulties,
2. to use interviews to gather information on the difficulties reported in everyday life, the causes, and the environmental conditions leading to a reduction in activity in a population of myopic patients with retinal complications.

The second phase will consist of a quantitative exploratory pilot study aimed at comparing the performance of diffuse choroidal atrophy (DCA) and choroidal patch atrophy (CPA) patients in order to highlight any differences between the two in tasks involving mobility and obstacle avoidance, visual search, and driving

Inclusion Criteria:

Patients with pathological myopia and diffuse choroidal atrophy (DCA, Cat. 2 Meta PM)

• Age ≥ 18 years and ≤ 55 years;
• Patient consenting to be included in the study;
• Examination and follow-up in at least one of the participating centers;
• Severe pathological myopia with an axial length ≥ 26.5 mm in both eyes;
• Presence of diffuse atrophy (category 2 of the Meta-PM classification) in the better eye;
• Affiliated with or covered by a social security system.

Pathological myopic patients with patch choroidal atrophy (PCA,

Cat. 3 Meta PM):

• Age ≥ 18 years and ≤ 55 years;
• Patients who consent to be included in the study;
• Examination and follow-up at least one of the participating centers;
• High myopia with an axial length ≥ 26.5 mm in both eyes;
• Presence of patch atrophy (category 3 of the Meta-PM classification) in the better eye;
• Affiliated with or beneficiary of a social security system.

Exclusion Criteria:

• Identified genetic syndromic myopia, including Stickler syndromes type 1 and 2 (collagen 2A1 and 11A1), Marfan syndrome (fibrillin), Ehler-Danlos syndrome type 4 (lysyl-protocollagen hydroxylase), and Knobloch syndrome (collagen 18A).
• Patient unwilling to participate or be followed up at one of the participating centers.
• Binocular visual acuity ≥ 1 logMar (<0.1 on the decimal scale).
• Media opacities preventing quality imaging, including cataracts.
• Patients benefiting from legal protection measures.
• Pregnant or breastfeeding women.
• Individuals who may not be able to tolerate the driving simulator.